Ionis Pharmaceuticals股价在盘前交易中上涨2%,此前美国食品药品监督管理局(FDA)为该公司一款神经疾病治疗药物授予了"突破性疗法"认定。
这一监管里程碑的达成推动了投资者对该生物技术公司的乐观情绪,突破性疗法认定通常意味着药物开发和审批流程的加速。
Ionis Pharmaceuticals股价在盘前交易中上涨2%,此前美国食品药品监督管理局(FDA)为该公司一款神经疾病治疗药物授予了"突破性疗法"认定。
这一监管里程碑的达成推动了投资者对该生物技术公司的乐观情绪,突破性疗法认定通常意味着药物开发和审批流程的加速。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.